Eyenovia Logo 311 x 109.png
Eyenovia to Participate in Panel Presentation at OSN New York 2018
19 sept. 2018 08h30 HE | Eyenovia, Inc.
NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia Logo 311 x 109.png
Eyenovia to Present at the Ladenburg Thalmann 2018 Healthcare Conference
18 sept. 2018 07h30 HE | Eyenovia, Inc.
NEW YORK, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia Logo 311 x 109.png
Eyenovia to Present at the 20th Annual H.C. Wainwright Global Investment Conference
21 août 2018 07h30 HE | Eyenovia, Inc.
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia Logo 311 x 109.png
Eyenovia Reports Second Quarter 2018 Financial Results
14 août 2018 06h30 HE | Eyenovia, Inc.
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia Logo 311 x 109.png
Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability
13 août 2018 08h30 HE | Eyenovia, Inc.
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia Logo 311 x 109.png
Eyenovia Announces Conference Call and Webcast for Second Quarter 2018 Financial Results
31 juil. 2018 08h30 HE | Eyenovia, Inc.
NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia Logo 311 x 109.png
Eyenovia Appoints Michael Rowe as Vice President of Marketing Ahead of Initiation of Multiple Phase III Programs
09 juil. 2018 07h30 HE | Eyenovia, Inc.
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia Logo 311 x 109.png
Eyenovia to Present at the JMP Securities 2018 Life Sciences Conference
11 juin 2018 07h30 HE | Eyenovia, Inc.
NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia Logo 311 x 109.png
Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Delivery
05 juin 2018 07h30 HE | Eyenovia, Inc.
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia Logo 311 x 109.png
Eyenovia Reports First Quarter 2018 Financial Results and Completion of EYN PG21 Study
09 mai 2018 06h30 HE | Eyenovia, Inc.
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print...